Dual VEGF-Targeting Strategy Via AAV2-Delivered sFLT-1 and shVEGF for Retinal Neovascularization Therapy.

ABSTRACT:

Purpose

Retinal neovascular diseases, often associated with elevated vascular endothelial growth factor (VEGF) levels, are major causes of blindness. Current therapies lack sustained efficacy and safety. This study aimed to evaluate the effectiveness of an adeno-associated virus 2 (AAV2)-based gene therapy vector carrying soluble fms-like tyrosine kinase-1 (sFLT-1) and short hairpin RNA targeting VEGF (shVEGF) in treating retinal neovascularization.

Methods

P12 mice were divided into six groups: normal group, control group, AAV2-EGFP group, AAV2-sFLT group, AAV2-shVEGF group, and AAV2-sFLT-shVEGF group. AAV2 vectors encoding sFLT-1 alone, shVEGF alone, or a combination of both sFLT-1 and shVEGF were administered to oxygen-induced retinopathy (OIR) mice via intravitreal injec

SUBMITTER: Chen C 

PROVIDER: S-EPMC12366864 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature